A Treatment to Cure Diabetes Using Plant-Based Drug Discovery
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Hindawi
Evidence-Based Complementary and Alternative Medicine
Volume 2022, Article ID 8621665, 12 pages
https://doi.org/10.1155/2022/8621665
Research Article
A Treatment to Cure Diabetes Using Plant-Based Drug Discovery
Sumalatha Mahankali,1 Jagadish Kalava,2 Yugandhar Garapati ,3
Bullarao Domathoti ,4 Venkata rao Maddumala ,5
and Venkatesa Prabhu Sundramurty 6
1
Department of Mechanical Engineering, Velagapudi Ramakrishna Siddhartha Engineering College, Vijayawada,
Andhra Pradesh 520007, India
2
Deaprtment of CSE, Dr.A. P. J. Abdul Kalam University, Indor, India
3
Department of CSE, GITAM Deemed to be University, Hyderabad, India
4
Department of CSE, Shree Institute of Technical Education, Tirupati, Andhra Pradesh 517501, India
5
Department of CSE, Vignan’s Nirula Institute of Technology and Science for Women, Guntur, Andhra Pradesh, India
6
Center of Excellence for Bioprocess and Biotechnology, Department of Chemical Engineering,
College of Biological and Chemical Engineering, Addis Ababa Sciecne and Technology University, Addis Ababa, Ethiopia
Correspondence should be addressed to Yugandhar Garapati; yugandhar.garapati@gmail.com, Bullarao Domathoti;
bullaraodomathoti@gmail.com, and Venkatesa Prabhu Sundramurty; venkatesa.prabhu@aastu.edu.et
Received 16 January 2022; Revised 14 February 2022; Accepted 4 March 2022; Published 9 May 2022
Academic Editor: Arpita Roy
Copyright © 2022 Sumalatha Mahankali et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The field of peptides and proteins has opened up new doors for plant-based medication development because of analytical
breakthroughs. Enzymatic breakdown of plant-specific proteins yields bioactive peptides. These plant-based proteins and
peptides, in addition to their in vitro and vivo outcomes for diabetes treatment, are discussed in this study. The secondary
metabolites of vegetation can interfere with the extraction, separation, characterization, and commercialization of plant proteins
through the pharmaceutical industry. Glucose-lowering diabetic peptides are a hot commodity. For a wide range of illnesses,
bioactive peptides from flora can offer up new avenues for the development of cost-effective therapy options.
1. Introduction hydrophilic states is one example of its structural abilities.
Peptide form and herbal pastimes are not inseparable, but it
Biomolecules play an important role in the ligand-reason is an essential part of their athletic activities [4]. Regardless
interactions, and their beautiful use in herbal structures of not peptides are bioactive or nutraceutical, they can have a
triggers the signalling cascade, which is an important aspect significant impact on an individual’s health [5]. Advances in
of daily life. In dreams, lipids, carbohydrates, and nucleic disease prevention and treatment, as well as scientific de-
acids occupy specific receptors. When all of the binding and velopments in lifestyle, metabolic, and immunological de-
structural alterations have been completed, a peptide is vice trends, are all contributing to an increase in human
released as a signal. A contamination can develop if a signal fitness [6].
transduction route fails [1, 2]. Those enzymes that break As with every drug, each peptide and protein treatment
down proteins into bioactive peptides are known as pro- has its own unique set of benefits and cons when it comes to
teolytic reagents. Bioactive peptides, which can contain up to sports injury rehab. With many advantages, however, they
twenty amino acids, do not interact with many proteins also have significant downsides that make them difficult to
because of their short half-life. Affinity for tissue and se- compete in today’s cutting-edge medication market [7]. The
lectivity, as well as above-average overall performance, are manufacture of protein necessitates a number of stages,
considered favourable conditions [3]. The ability of a pep- many of which are expensive. Because oral protein ab-
tide’s backbone to switch between hydrophobic and sorption is limited, a move to parenteral nutrition may be2 Evidence-Based Complementary and Alternative Medicine
desirable [8]. Between 2018 and 2026, the global peptide visceral organs such as the heart and lungs, which are already
therapeutics market is expected to grow at a CAGR of 9.1% the most commonly concerned devices [21].
(2016). Insulin’s use as a recovery peptide accounts for a Several sources were employed to synthesize exenatide,
significant portion of the market. J.B. Collip, along with which was generated from the peptide exendin-4 first ob-
Frederick Banting and Charles Best, became the first person tained from the Gila monster (Heloderma suspectum) [22].
to successfully isolate insulin from a variety of animal Despite their structural similarity to GLP-1, liraglutide and
sources, thanks to their combined efforts [9]. The biosyn- semaglutide have a longer half-life and are not destroyed by
thetic insulin brand Humulin was introduced by Eli Lilly and DPP-IV [23]. Recombinant DNA technology has made it
Company in 1983. Insulin was first derived from animal possible to generate large quantities of these peptides.
pancreases by a for-profit enterprise. 88.7% of the insulin Synthetic or recombinantly produced peptides are more
market is dominated by Novo Nordisk, Sanofi, and Eli Lilly expensive than tiny molecules, making them out of reach for
together. Some 22 and two-thirds of the top ten antidiabetic the general people. Peptide-based pharmaceuticals and
medicine businesses owe money to Sanofi’s Lantus, a drug herbal-based fitness items have grown increasingly popular
manufactured by the company (basal insulin). Lantus had a [24]. Bioactive peptides derived from animal proteins have
revenue of $6.057 billion in 2016. The year 2017 saw the been the subject of numerous clinical studies. Discovery of
release of Dezzani [10, 11]. While the FDA classifies small useful leads from plants to improve diabetic patient care is
molecules and peptides as “New Chemical Entities,” proteins made possible by researchers’ excursions into bioactive
used to treat a wide range of diseases are referred to as “New peptides [25].
Biological Entities” (NBEs).
Therapeutic peptides can be used to treat a wide range of
medical conditions, including cancer, diabetes, and obesity 1.1. Extracts of Plant Peptides with Bioactive Qualities.
(Figure 1). When it comes to treating type 2 diabetes, Novo Bioactive peptides have been overconcentrated in both
Nordisk’s liraglutide (Victoza) has been the top-selling animal and plant resources [26]. Bioactive peptides are
peptide medical medicine in recent years [13], [14]. Gla- found in animal products such as milk, eggs, meat, and fish
tiramer acetate, a Teva-developed immunomodulator, is that are easily accessible to the general population. There are
used to reduce the symptoms and signs and symptoms of only a few bioactive peptides that have been isolated from
patients with multiple sclerosis [15]. Abbott’s leuprolide soy, wheat, and other cereals [27]. In animals, overcon-
(Lupron), a hormone responsive therapy, is utilised in the sumption of protein has been linked to a variety of health
treatment of most cancers and estrogen-based diseases [16]. issues, including high blood pressure, heart disease, and
In the treatment of breast and prostate tumours, the go- stroke. Plant-based proteins, on the other hand, do not
nadotropin-liberating hormone agonist Zoladex is syn- include fat or produce bad results [28]. As studies have
thesised by Astra Zeneca and reduces the release of sex advanced toward a fuller understanding of floral signalling, a
hormones [17]. Companies like Amgen, Eli Lilly, Roche, and new and well defined component in mobile-to-cell com-
Pfizer are also researching peptide or protein-based thera- munication has emerged: secreted peptides, short RNAs, and
pies in order to shorten the market advantage for treatment transcription factors [29–31]. Plant and animal-derived
of more advanced problems [13]. signalling peptides have now been established to be bio-
It has become more difficult to analyse and purify these synthesized in a similar manner, despite some of the
compounds, thanks to new analytical systems, cutting-edge components of the biosynthesis still being unknown. Early
purification techniques, and in vitro tests. However, there development techniques such as meristem boom, organ loss,
has been a lot of interest in the use of plant secondary cell elongation, cell multiplication, cell differentiation, and
metabolites, which contain small molecules, to transport invasion defence make extensive use of plant-derived pep-
new capsules to combat disease spread [18]. tides [32]. It has been hypothesised that mediator proteins
The discovery of primary metabolites, proteins, and and peptides evolved in microorganisms and were even-
peptides derived from plants has given rise to a new type of tually integrated into higher mediator systems in sophisti-
examination challenge as shown in Figure 2 [19]. With cated animals at some unknown point in time during
peptide-based treatments for diabetes becoming more evolution [33]. The peptides found in Spinacia oleracea
common, the challenges of creating peptide-based medicines L. were among a slew of hormone-like compounds found in
and the potential of peptides as healing treatments were also flowers. Furthermore, Lemna gibba G3, in addition to the
discussed. ones found in oats and alfalfa as well as the luteinizing Avena
Has the potential to totally reverse the diabetes. Oral sativa L. Consider the fact that signalling peptides were
hypoglycemic medications are commonly used to manage discovered a few billion years ago in the fossil record to
type 2 diabetes. One of the most commonly prescribed support this idea [34–37]. Plant proteins, which contain
medications is metformin, which is supplemented by hy- essential amino acids, are an excellent source of nutrition for
poglycemic agents from a wide range of classes as given in humans. From leaves to the finished product, there are three
Table 1 [20]. These include thiazolidinediones, alpha-glu- types of plant proteins. Seeds (legumes and grains) have a
tamyl transferases, sulphonylureas, and DPP-IV and SGLT- higher protein content than vegetables, and this is reflected
2 inhibitors. Hypoglycemia, fatigue, diarrhoea, and anaemia in the finished product [38]. Bean seeds from Vicia faba and
risk are all associated with these therapies. As these side Lupinus albus have a protein content of 18–20%, but bean
effects compound over time, they put additional strain on seeds from Glycine max and Lupinus albus have a proteinEvidence-Based Complementary and Alternative Medicine 3
20
18
% uses of therapeutic
16
protein drugs (%)
14
12
10
8
6
4
2
0
infectious disorder
others
Cardiac disorder
Gentetic disorder
Hormonal disease
Cancer
metabolic disorder
immunological disorder
Hematological disorder
Figure 1: Diabetic discovering from various disorders [12] (Statement Note: In the figure legend reproduced from Patil S.P.,
Goswami A., Kalia K et al.’ Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes. Int J Pept Res Ther 26, 955–968 (2020).
https://doi.org/10.1007/s10989-019-09899-z).
Diabetic population (Million)
200
180
160
140
120
100
80
60
40
20
0
America Europe Soviate Rasia India Oceanic and Astralia South Africa
pacific island
2016
2050
Figure 2: Population wise country report of diabetics [19].
Table 1: Types of diabetics and its methods [20].
Type Method
Type 1 diabetic (juvenile) Decreased insulin
Type 2 diabetic Glucose storing cells developing insulin resistance
Type 3 gestational diabetes Increased danger of health issues
Type 4 other diabetes For pregnancy women
value of 35–45% (soybean). It is Lupinus albus L. (lupin) a reduction in absorption. In light of these findings, it was
[39]. concluded that postprandial plasma glucose levels were
Extraction of antibioactivity peptides and hydroysate significantly lower than they were on a daily basis. Inhibitors
from plants from bioplants is shown in Figure 3 [40] and of this enzyme may cause beta mobile pressure to decrease
benefits are shown in Tables 2 and 3 [20]. (thus decreasing postmeal hyperglycemia) and the pro-
duction of glucagon-like peptide-1 (GLP-1) to increase (thus
increasing insulin secretion) as a result [41, 42]. A reduction
1.2. Alpha-Glucosidase Inhibitor. Alpha-glucosidase inhib- in postprandial hyperglycemia in diabetics will raise their
itors compete with enzymes in the intestine that break down risk of developing macrovascular issues, which can be
nonabsorbable polymers into monosaccharides, resulting in minimised by the administration of insulin throughout the4 Evidence-Based Complementary and Alternative Medicine
fractions with molecular weights of 1 kDa and above, a
Food
Processing Function of Microbial protein-rich extract of Phaseolus vulgaris L. (Pinto Durango
Applications Peptides glucosidase and Negro 8025) beans was hydrolyzed and ultracentrifuged,
inhibitor
and the results revealed that 76% of 0.5% enzyme inhibition
was observed [49]. Protein samples from Phaseolus vulgaris
Curing (black bean) were incubated for hours with an enzyme to
Plant Based Bio Active Peptides rDNA via substrate ratio (E/S) of 1:20 and a 66.1% inhibition of alcalase
materials Expression
cells hydrolysis, as determined by an enzyme to substrate ratio (E/
S) of one to twenty. After in vitro digestion of Chenopodium
quinoa Willd. (quinoa) protein, LC–MS/MS was used to
Peptide
identify well-known bioactive peptides with amino acid
Synthesis sequences such as IQAEGGLT, DKDYPK, and
reports GEHGSDGNV, among others. At a concentration of 250
million millimetres, it was discovered that enzyme inhibition
Figure 3: Proposed structure of bioactive peptides [40]. was 55%, 22%, and 30% at different levels of concentration
[50]. Using Morus alba L. (mulberry) leaves, researchers
meal [42, 43]. The inclusion of a glycemic opportunity in discovered that they could produce an oligopeptide with
those items aspires to lessen glucotoxicity while also in- molecular weights ranging between 0.5 and 3 kDa that
creasing beta mobile insulin production in the body [41, 44]. inhibited enzymes at a concentration of 12.56 g/ml [51]. A
Despite the fact that peptides make up the majority of the protein that is contained within the form of the plant,
alpha-glucosidase inhibitors that are commercially available, Momordica cymbalaria, is presented by Hook.f. (Momordica
there are no peptide-based alpha-glucosidase inhibitors cymbalaria). In animal studies, it has been demonstrated
available on the market. Peptides derived from flowers have that inhibiting enzymes responsible for a decrease in glucose
been used in several studies to inhibit the enzyme alpha- production helps to improve the carbohydrate metabolism
glucosidase. An enzyme-blocking peptide derived from [52].
hemp seeds contained branched-chain amino acids, hy-
drophobic amino acids, and essential amino acids, all of
which were discovered to be present [45]. The hydrolysate of 1.3. Inhibitors of Alpha-Amylase. As part of the process of
oat seed proteins is broken down by a protease (alcalase), converting nonabsorbable polysaccharides into absorbable
producing bioactive peptides that have the ability to block monosaccharides [53], amylase (α-1,4-glucan-glucanohy-
the activity of the enzyme alcalase. Additional findings were drolase) aids in weight loss by increasing carbohydrate and
obtained by an in vivo examination. With an increase in the starch hydrolysis (α-1,4 glycosidic linkage) and decreasing
dosage of oat peptides administered to STZ-induced diabetic fat absorption [54]. Amylase inhibitors lower blood glucose
mice, the amount of food consumed reduced while insulin levels after a meal as a result of the fact that they delay the
production increased. The diabetic mice also demonstrated digestion of carbohydrates and the absorption of glucose
improved glucose tolerance and glycogenesis [46]. Hydrated into the bloodstream [55].
peptides produced from the fruit proteins of Juglans man- It is possible that pinto beans, despite the fact that they
dshurica Maxim were selected as antidiabetic agents for have not been extensively studied, may also have some
clinical trials (walnut). These chemicals work by interfering health benefits. It had been decided to dialyze the hy-
with the enzyme responsible for sugar breakdown in the drolyzed fraction for 1 h at 50°C with an (E/S) ratio of 1 : 10,
body. We discovered that WHPs with molecular weights and the fraction obtained with molecular weight tonnes an
ranging from 3 to 10 kDa had an inhibitory effect on alpha- awful lot a good deal less than 3 kDa revealed 62% and 3%,
glucosidase in vitro, with a 67% inhibitory effect. respectively. 49% and 5% enzyme inhibition, respectively,
Extracellular glucose absorption by insulin-resistant were observed during the enzymatic digestion of the pinto
HepG2 cells is significantly increased as a result of the use of bean protein fraction employing protease (Protamex) at pH
this cell type. Several studies have demonstrated that WHPs 6 [56]. Dialysis and bromelain (protease) were thought to
can lower blood glucose levels by means of lowering insulin be particularly effective at inhibiting enzyme activity. Only
manufacture, liver glucokinase interest, and glycogen levels one-fourth of 1% is consistent with the previous year [49].
by 64.8% in domestic individuals ordinary [47]. In diabetic The alpha-amylase inhibitory peptide CSP1, which was
version KK mice, researchers discovered enzyme inhibitory derived from cumin seed, lowered alpha-amylase activity
properties in proteins derived from the adzuki bean Vigna by 24.54% points in vitro [57]. It was discovered that
angularis Wild (KK-Ay), which was discovered by chance. In Triticum aestivum L. (wheat) albumin extract inhibited the
the hours following a meal, the extract helps to reduce enzyme alpha-amylase, resulting in reduced blood glucose
postprandial blood sugar levels. In the presence of sucrose levels following a meal as a result. Postprandial glucose
challenge conditions, the glucose levels of regular rats and levels have been lowered by using 31% of the dose at the
rats treated with streptozocin were 15.6% and 29.9%, re- same time as using 0% of the dose. For 25 g sample, the
spectively. The presence of adzuki bean proteins at a con- answer is zero. 5 g and 100 g of wheat albumin were used
centration of 10 mg/mL in vitro inhibits the activity of rat and the answer is zero. Although the addition of 5 g wheat
intestinal alpha-glucosidase by 60% (2014) [48]. In peptide albumin had no effect on fasting blood glucose levels, it didEvidence-Based Complementary and Alternative Medicine 5
Table 2: Plants possessing antibioactivity for diabetics [20].
S. no. Plants Used sequence
1 Babul Sore throat
2 Aloe vera Changes in urine colour and vomiting are among the side effects that can accompany bulimia.
3 Garlic Immune system booster; reduces hypertension; antibacterial and antifungal qualities
4 Beetroot Improve the condition of hypertension
5 Neem Pain, fever, and infection are all symptoms of infection.
6 Church steeples Cultural porphyria is a skin ailment.
Table 3: Hydrolysate from plants for antidiabetic activity [40].
S.
Plants Part Activities
no.
Different hypoglycemic and insulin substances, as well as glycans such as panaxan A
1 Araliaceae Roots through P and ginsenoside Rb1, have been identified from the roots of diverse plants.
Antilipolytic properties have been attributed to a number of substances.
2 Rhodophyta Leaf C was found to contain two distinct polypeptide fractions.
Fruits and Momordica charantia was used to produce p-insulin, which was extracted from the
3 Cucurbitaceae
seeds fruit, seeds, and tissue (bitter gourd)
The protein A. melanoxylon and B. retusa, which was isolated from seeds, was
4 Leguminosae Seeds
investigated.
Fruits and Momordica cymbalaria significantly reduced fasting plasma glucose levels in diabetic
5 Fenzl
seeds mice caused by streptozotocin.
Coix lacryma-jobi L. var. ma- Adlay grains have a significant amount of prolamin, which is an alcohol-soluble
6 Grains
yuen Stapf. protein belonging to the prolamin group.
7 Oryza sativa Rice bran Insulin resistance was improved by consuming a functional meal.
have a positive effect on haemoglobin A1c levels, which are at 250 mg/ml after enzyme hydrolysis of quinoa proteins,
a measure of diabetics’ metabolic control, in an extended- according to the results of the experiment [50].
term manipulation study [58]. It has been determined
through research that Hordeum vulgare (barley) flour has
been submitted to pancreatic hydrolysis and that peptides 1.4. Dipeptidyl Peptide IV Inhibitors. Incretin hormones,
isolated from the flour have a 57–77% inhibitive impact on such as GLP-1 and GIP, are two of the most significant gut-
the enzyme alpha-amylase. Cucurbitin, a protein found in derived hormones, and their role in controlling blood
the seeds of Cucurbita pepo L. pumpkins, has been shown glucose levels is well-known [62]. Along with the decrease in
to inhibit the hydrolysis of alcalase and pepsin, two en- appetite and insulin release, the level of the hormone glu-
zymes involved in digestion. The C50 value for mulberry cagon also decreases [63]. The incretin hormone is released
oligopeptides has been increased from 12 to 14. It is be- at a lower rate in diabetics. These hormones display their
lieved to have the most inhibiting reputation at a con- herbal consequences as they link with receptors in the colon
centration of 25 g/ml. Laminar go together with the flow. [64]. A return to normal hormone production or a reduction
Moringa oleifera (moringa tree) extracts of protein hy- in hormone breakdown is an aspect of diabetes treatment.
drolysates from seeds have been developed. The enzymes GLP-1 is degraded with the help of DPP-IV within minutes
trypsin, chymotrypsin, and pepsin-trypsin are utilised for of its creation, leaving it without any herbal trends. Inhi-
the first two and a half and five hours, respectively. The use bition of DPP-IV could be a useful tool in the fight against
of the pepsin-trypsin digested fraction for hydrolysis in- hyperglycemia. DPP-IV inhibitors enhance GLP-1 post-
tervals of 5 h and 5 h, respectively, for alpha-amylase in- prandial effects by delaying GLP-1 breakdown, which lowers
hibition was validated, with IC50 values of 0.195 and hepatic glucagon era, activates pancreatic beta cells, and
0.123 g/ml, respectively, confirming the findings of the raises insulin levels.
previous research [59]. The IC50 for alcalase hydrolysate With an IC50 cost of 1.450, dipeptides produced from
was modified and determined to be 0.149 mg/ml for protein rice bran protein hydrolysate inhibited the DPP-IV enzyme.
hydrolysate of watermelon seeds received with the useful 13 mg/ml protein was from rice bran [65]. Rice bran
beneficial resource of enzymes together with pepsin, protein fractions were defatted and hydrolyzed using Bio-
trypsin, and alcalase [60]. Three different PH values were prase SP and Umamizyme G in pioneering research. Fol-
employed to construct Theobroma cacao L. that give up end lowing dipeptide digestion with Umamizyme G, IC50 was
outcome autolysates: 3.5, 5.2, and 5.3. In vivo tests showed discovered to be 2.3, 0.1 mg/ml [66]. Proteins from Amar-
that when the autolysate has emerged at pH 3.5, alpha- anthus hypochondriacus L. were employed to make bioactive
amylase inhibition and insulin launch have been maxi- peptides by simulating gastrointestinal digestion. With an
mised and blood glucose stages have been decreased [61]. IC50 of 1.1 mg/ml, this peptide fraction has been shown to
Quinoa protein fractions reduced alpha-amylase by 6.86% inhibit enzymes dose-dependently [67]. Glycine max6 Evidence-Based Complementary and Alternative Medicine
L. (soybean), Lupinus albus, and Lup 1 protein hydrolysate blocking tyrosine phosphatase from dephosphorylating in-
all included DPP-IV inhibitory peptides. Soy 1 and Lup 1 sulin receptors, reducing insulin sensitivity [76].
were inhibitory peptides with IC50 values of 106 and 228 M, According to the radioimmunoassay, spinach and
respectively [68]. CPGNK and GGGLHK, herbal peptides Lemna gibba G3 extracts imitate mammalian insulin.
derived from the protein digestion of not top-notch beans, According to an in vivo study in extra young rats, a plant
inhibited enzyme activity with IC50 values of 0.87, 0.02, and insulin-like fibre interacts with insulin receptors on IM-
0, respectively. In the neighbourhood, there are 610.10 9 lymphocytes and supplements glucose oxidation and li-
peptides (Mojica et al., 2017, [69, 70]). Proteins produced pogenesis in distant adipocytes [34]. Antioxidant and blood
from Phalaris canariensis L. (Canary) seed inhibited DPP-IV glucose-lowering chemicals found in Vigna unguiculata
digestion in the gastrointestinal tract by 40% [71]. The IC50 L. (cowpea) have aided patients. Over the course of 20 h,
for papain inhibition of quinoa proteins was reported to be researchers delivered extremely high dosages of cowpea
0.88 for 0.05 mg/ml using hydrolysate-papain hydrolysate peptides (0.1, 1, 10, and 100 ng) and insulin (100 nM) to L6
[72]. Quinoa protein was employed to complete a simulated skeletal muscle cells. A Western blot analysis of proteins
duodenal digestion, and the IC50 (mg protein/mL) was from treated cells is also being utilised to determine whether
found to be zero. The amount of protein per millilitre is or not Akt activation has occurred (a form of protein kinase
840.007 [50]. B; PKB). Cowpea peptides can phosphorylate Akt during cell
implantation, consistent with the findings of the study.
Cowpea peptides can stimulate insulin signalling in skeletal
1.5. Transporter Inhibitors for Glucose (GLUT and SGLT). muscle cells, which is consistent with previous research.
In order for glucose to pass through the lipid bilayer of the Cowpea peptides can act as a substitute for insulin by du-
membrane, membrane proteins (glucose transporters) plicating its signalling function [77].
function along the lipid bilayer [20]. Glucose is passively Peptides synthesised as seed peptides from Linum usi-
transported by GLUT transporters, which do not require tatissimum (flax) protein hydrolysate (50 kD) outperform L6
energy to function, but active glucose transport by SGLT mobile glucose uptake [78]. Arrived: peptide fraction from
transporters necessitates energy. This method results in salt Momordica charantia L. Hypoglycemia is most likely di-
transfer from one location to another, so that glucose can be agnosed by an in-person or in-female examination. The
added to the membrane’s route [73, 74]. In the human body, MC2-1-five fraction lowers blood glucose levels with a
there are at least 12 extraordinary GLUT transporters and 7 useable resource of 61.70% and 69% of the total population,
remarkable SGLT transporters, all of which may be mem- respectively. Alloxan-treated diabetic rats lost 18% of their
brane-elastic protein members. The proximal tubule reab- bodyweight in just 4 h [79]. For a minute, examine the
sorbs 90% of the ejected glucose, whereas the distal tubule protein in Momordica charantia L. pulp. Insulin secretion
reabsorbs the remaining 10%. and glucose levels were both reduced in C2C12 and 3T3L
In response to high blood glucose levels (hyperglycemia), adipocytes when a protein derived from pulp was supplied to
the proximal tubule detects an increase in the expression of a the cells, in accordance with an in vivo examination [80],
glucose transporter gene [20]. Peptides that specifically [81]. Insulin uptake and clearance are improved in diabetic
target plant glucose transporters have been tested in a mice, thanks to the useful resource of in vitro digestion of the
limited number of cases to a great effect. Antiglycose plant-derived insulin receptor binding protein (mcIRBP),
transporter inhibitors with amino acid sequences AKSPLF which has 68 residues, to provide mcIRBP-19, which in-
and ATNPLB have been demonstrated to be effective in the creases insulin receptor binding and activates PDK1, Akt,
treatment of diabetes. After 24 h of therapy with the Caco-2 and the expression of glucose transporter 4, McIRBP-19
cellular version, the bioactive peptides examined reduced [40]. Momordica cymbalaria L. fruit’s 17 kD protein, Mcy
glucose reabsorption by 21.5%. The oral glucose tolerance protein, has been studied in vivo for its hypoglycemic effects
test in rats after 50 mg of hydrolyzed protein isolate/kg BW [82]. It was further confirmed that the peptide fraction
showed a 24.5% reduction in postprandial hyperglycemia (P improved glucose absorption in muscle cells by activating
0.05) (Mojica et al. 2004). AMK, a cellular enzyme [83].
Researchers discovered that when they were given a
protein extract produced from the Cucurbitaceae family of
1.6. Insulin Replacement Remedy. Insulin regulates the seeds, which includes Telfairia occidentalis Hook.f., Citrullus
metabolism of a weight loss plan via a series of signalling lanatus L., Lagenaria siceraria Molina, and Cucurbita
pathways [22]. In response to insulin, the alpha subunit of moschata Duchesne, their blood sugar levels plummeted
the insulin receptor undergoes conformational changes, dramatically [84]. A peptide isolated from Bauhinia varie-
which activates cytoplasmic tyrosine kinase. As a result, gata L. leaves mimics insulin in terms of immunological
insulin transphosphorylates additional intracellular sub- reactivity and in vivo detection [85]. Studies on Zea mays
strates before activating the insulin receptor. When these L. (Zein) seed protein hydrolysate in GLUTag cellular lines
outcomes are coupled, they have severe effects on metabolic revealed that it increased the synthesis of the hormone GLP-
and mitogenic structures [75]. The activation of tyrosine 1 in rats’ ileum and duodenum [86]. Glycine supplements
kinase by insulin mimics has implications for receptor the production of p-IR, p-IRS1, and the membrane-GLUT4
autophosphorylation and downstream insulin signalling. protein to reverse the hypoglycemia effects of diabetic mice
Furthermore, the insulin mimic (vanadate) functions by on C2C12 cells. In C2C12 ells, glycine improves glucoseEvidence-Based Complementary and Alternative Medicine 7
absorption [87]. Soymorphine-5, also known as opioid, 1.8. The Destiny of Peptide-Based Totally Therapeutics Is
reduces blood glucose levels in diabetic KK-Ay mice through Brilliant. Therapeutic peptides are becoming increasingly
activating the adiponectin and PPAR systems [88]. Insulin popular because of the fact that peptides are more strong,
sensitivity has improved, and metabolic issues have been selective, and easy to use than small compounds. There is a
addressed with the help of rice bran protein hydrolysate [89]. good chance that this trend will continue in the future
To isolate the protein, the fruit pulp of the Momordica dioica [98, 99]. Researchers and pharmaceutical companies can use
Roxb fruit was employed. Even when taken in its diabetic ordinary synthesis and drug format approaches to multiply
form, this medication lowers diabetics’ blood glucose levels peptide-based totally in reality therapeutic possibilities.
[90]. Peptides similar to insulin or peptides meant to imitate Using a recombinant protein from bacteria, yeast, or fungi, a
insulin are also thought to be present in the blooms of ex- desired peptide can be synthesised [100]. Artificial peptide
traordinarily excellent plants by a variety of plant scientists [91]. synthesis has progressed to the point where it can mimic the
effects of natural peptides without relying on animal de-
livery. One of the advantages of peptides that can be drug-
1.7. Overcoming Obstacles with Peptide Drugs. Success and conjugated is that they have several functionalities [98].
popularity are directly linked to how quickly and easily a There is a risk of peptide breakdown when being fed on,
treatment may be implemented [64]. As the vast majority of despite the fact that the most convenient form of delivery is
medicines on the market today are taken orally, oral peptides. The most common method is intravenous peptide
medication substitution is the most well-known and widely manipulation; however, new studies are being conducted in
used technique [92]. The stomach’s environment can be this area. Attempts have also been made to give the drug
experienced by bypassing the gastrointestinal membrane orally and transdermally via intranasal administration.
with energetic tablets taken orally. Small molecules, in Peptides may be used to aid in the diagnosis of disease due to
contrast to large macromolecules that dissolve in the gas- their attractiveness as symptoms. Vaccines can also benefit
trointestinal system and cannot be permeable in their intact from the use of peptides, as has long been shown [95, 101].
form to collect a specific cause without degradation, can Researchers employed the same techniques shown in
remain on the stomach pH and bypass the barrier [92]. As Figure 4 [94] to isolate and characterise plant peptides. The
the medical period progresses, an increasing number of combination of X-ray crystallography and nuclear magnetic
peptide drug therapies are being examined for their resto- resonance (NMR) has greatly assisted herbal peptides
ration potential in the treatment of a wide variety of ailments (Figure 3). Natural peptide shapes have benefited greatly
[93]. There has been a longstanding problem with oral from advances in X-ray crystallography and nuclear mag-
bioavailability of peptide-based totally medications despite netic resonance (NMR) [102].
the fact that their genuine goal, usefulness, and effectiveness Characterization techniques such as electron micros-
are accurate. Peptide medications have a high rate of side copy, fluorescence resonance energy transfer, and chemical
effects, which is a major downside [62]. Recombinant peptide flow-linking have advanced in the previous year [103], [104].
synthesis is a method by which biotechnology’s successes can Peptide combinations can be thoroughly investigated using
be achieved at lower costs and with less strength. Bioactive mass spectrometry, which finds the best possible form for
peptides derived from natural resources are gaining com- each and every one. There are numerous approaches for
mercial interest, but large-scale production has been ham- mass spectrometry-based amino acid sequencing, including
pered due to lack of adequate generating methods [94]. facet pinnacle-down and bottom-up. The molecular weight
The half-lives of peptide-based therapy pills are often can be estimated in pinnacle-down sequencing without
only a few hours long, which is a source of concern. Peptides hydrolysis by using the intact protein fragmentation pattern.
are broken down into amino acids by stomach acid and Down-top sequencing, in which proteolytic digestion is
blood peptidases, which are quickly eliminated from the completed prior to MS analysis, is a frequent approach.
body and cause a decrease in the peptide half-life. It is Protein identification software application is available, and it
imperative that peptides be adjusted to be more long-lasting is based entirely on the amino acid collection’s criteria [105].
and less hazardous because of their half-lives. More and
more importance are being placed on nondegradable 2. Discussion
polymers and polymeric matrix as peptide treatments adorn,
with a reduction in the famed dose timetable being taken Plants, on the other hand, are an excellent resource for
into account [95]. Enzymes can be used to replace amino cultivating an entirely unique therapeutic candidate. A small
acids that are prone to cleavage, which further improves the fraction of the most well-known drugs and lead will be used.
peptide’s half-lifestyles [7]. Peptide oral delivery has been In the meantime, plants are being studied for the production
tested in the past, but its application is limited due to the fact of proteins and bioactive peptides for the treatment of
that the GI system breaks down peptides [96]. Novo Nordisk ailments, since the focus of study has shifted from small
has developed an oral version of semaglutide in the early molecules to biomolecules due to numerous advantages.
stages of clinical studies. Oral medication delivery has one of Plant hormones have long been thought to be the most
the main downsides, which can be mitigated by the em- ultramodern way for cells to communicate, despite the fact
ployment of noninvasive methods such as nasal and pul- that plant proteins and their homes have just recently begun
monary channels that give recuperation and healing to be seen. As our understanding of those signalling path-
strategies to the circulation immediately [97]. ways expands, a variety of secreted peptides and short RNAs8 Evidence-Based Complementary and Alternative Medicine
1. Autolysis
2. Enzymatic
Plant Protein Hydrolysis Peptides
material 3. Fermentation
• CEC • IEX
• FPLC • SEC
Separation
Anti diabetic • RP-HPLC • HPLC
Antioxidant
ACE Pharmacological
inhibitory activities Characterization
Anti cancerous Antimicrobial ESI-MS MALDI-TOF
Figure 4: Plant peptides being isolated, purified, and characterised in accordance with current best practises [94].
are being proposed as means to control cellular commu- consequences. It is believed that the bioactive peptides
nication by changing molecular structure. After gastroin- derived from flowers inhibit alpha-glucosidase, alpha-am-
testinal digestion, proteins can be transformed into bioactive ylase, DPP-IV, and glucose transporter systems. A plant
peptides with a greater tissue affinity for a specific receptor. peptide fraction has been examined in vivo and positioned to
Several recent studies have emphasised plant proteins and have insulin-mimicking homes in animals. Plant-derived
their bioactive peptides as a potential competitor in the bioactive peptides are underutilised in assessment of unique
treatment of a number of illnesses, particularly metabolic herbal product lessons. Peptides from plant reminiscence
and lifestyle-related illnesses such as cancer, diabetes, and cannot be recognized, purified, and studied because there are
weight problems. A cutting-edge methodology and technical not any good enough instrumental strategies. This can be an
leap forward allows for the clean isolation, purification, and extremely good time to start strolling with the plant peptides
characterization of proteins and peptides in a short amount of your choice, way to modern advancements in LCMS, LC-
of time, reducing the overall length of the invention process. NMR, and X-ray crystallography. In the future, plant peptide
The bulk of bioactive peptides used to treat diabetes studies must benefit from the systematic test that involves
appears to have come from synthetic or recombinant pro- dereplication for early peptide identification, goal identity,
duction, and each of them is most likely included in the and in vivo trying out.
drug’s daily dosage. Plant-based biomolecules may be
necessary to make peptide therapy more cost-effective. This Data Availability
research is based on bioactive peptides extracted from a
number of plant components, including leaves and seeds, The data used to support this study are included within the
and stop results. Although bioactive peptides can be found in article and are available from the corresponding author
leaves, pulps, and entire preventive outcomes, seeds are upon request.
thought to provide the greatest bioactive peptides to the
general public. Disclosure
Protein hydrolysate derived from plant aqueous extracts
has been shown to disrupt the enzymes and transporter sys- This study was performed as a part of the employment.
tems that cause diabetes, through in vitro and in vivo exper-
iments. An exciting journey into the molecular structures and Conflicts of Interest
mechanisms of action of plant-based totally bioactive peptides
The authors declare that they have no conflicts of interest.
is required, as well as a fantastic method for using those
bioactive peptides as a capability restoration option.
Acknowledgments
3. Conclusion The authors thank Velagapudi Siddhartha Engineering
College, Vijayawada, Dr. A.P.J. Abdul Kalam University,
Treatments for type 2 diabetes based mostly on artificial Indore, and Shree Institute of Technical Education, Tirupati,
pharmaceutical capsules have been proved in epidemio- for providing characterization supports to complete this
logical studies to cause minor to extreme terrible facet research work.Evidence-Based Complementary and Alternative Medicine 9
References [17] N. Magon, “Gonadotropin releasing hormone agonists:
expanding vistas,” Indian Journal of Endocrinology and
[1] L. Otvos Jr. and J. D. Wade, “Current challenges in peptide- Metabolism, vol. 15, no. 4, p. 261, 2011.
based drug discovery,” Frontiers of Chemistry, vol. 2, p. 62, [18] R. Verpoorte, “Exploration of nature’s chemodiversity: the
2014. role of secondary metabolites as leads in drug development,”
[2] N. Gautam, “Defects in signal transduction proteins leading Drug Discovery Today, vol. 3, no. 5, pp. 232–238, 1998.
to disease,” in Introduction to Cellular Signal Transduction, [19] L. Otvos, “Peptide-based drug design: here and now,” in
A. Sitaramayya, Ed., Springer, Boston, MA, USA, 1999. Peptide-Based Drug Design, L. Otvos, Ed., Humana Press,
[3] N. P. Möller, K. E. Scholz-Ahrens, N. Roos, and Totowa, NJ, USA, 2008.
J. Schrezenmeir, “Bioactive peptides and proteins from [20] M. A. Abdul-Ghani, L. Norton, and R. A. Defronzo, “Role of
foods: indication for health effects,” European Journal of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the
Nutrition, vol. 47, no. 4, pp. 171–182, 2008. treatment of type 2 diabetes,” Endocrine Reviews, vol. 32,
[4] Y. Li and J. Yu, “Research progress in structure-activity no. 4, pp. 515–531, 2011.
relationship of bioactive peptides,” Journal of Medicinal [21] D. M. Nathan, J. B. Buse, M. B. Davidson et al., “Medical
Food, vol. 18, no. 2, pp. 147–156, 2015. management of hyperglycemia in type 2 diabetes: a con-
[5] D. Kitts and K. Weiler, “Bioactive proteins and peptides from sensus algorithm for the initiation and adjustment of ther-
food sources. Applications of bioprocesses used in isolation apy: a consensus statement of the American diabetes
and recovery,” Current Pharmaceutical Design, vol. 9, no. 16, association and the European association for the study of
pp. 1309–1323, 2003. diabetes,” Diabetes Care, vol. 32, no. 5, p. e59, 2009.
[6] L. Vitetta, B. Anton, F. Cortizo, and A. Sali, “Mind-body [22] L. R. Aramadhaka, A. Prorock, B. Dragulev, Y. Bao, and
medicine: stress and its impact on overall health and lon- J. W. Fox, “Connectivity maps for biosimilar drug discovery
gevity,” Annals of the New York Academy of Sciences, in venoms: the case of gila monster venom and the anti-
vol. 1057, no. 1, pp. 492–505, 2006. diabetes drug byetta,” Toxicon, vol. 69, pp. 160–167, 2013.
[7] C. Adessi and C. Soto, “Converting a peptide into a drug: [23] D. J. Edmonds and D. A. Price, “Oral GLP-1 modulators for
strategies to improve stability and bioavailability,” Current the treatment of diabetes,” in Annual Reports in Medicinal
Medicinal Chemistry, vol. 9, no. 9, pp. 963–978, 2002. Chemistry, D. J. Edmonds and D. A. Price, Eds., Elsevier,
[8] T. Uhlig, T. Kyprianou, F. G. Martinelli et al., “The emer- Amsterdam, Netherlands, 2013.
gence of peptides in the pharmaceutical business: from [24] A. Henninot, J. C. Collins, and J. M. Nuss, “The current state
exploration to exploitation,” EuPA Open Proteomics, vol. 4, of peptide drug discovery: back to the future?” Journal of
pp. 58–69, 2014. Medicinal Chemistry, vol. 61, no. 4, pp. 1382–1414, 2018.
[9] C. C. Quianzon and I. Cheikh, “History of insulin,” Journal of [25] E. Daliri, D. Oh, and B. Lee, “Bioactive peptides,” Foods,
Community Hospital Internal Medicine Perspectives, vol. 2, vol. 6, no. 5, p. 32, 2017.
no. 2, Article ID 18701, 2012. [26] B. Ahrén, “Dipeptidyl peptidase-4 inhibitors,” Diabetes Care,
[10] L. Dezzani, Bloomberg Markets Top 20 Diabetes Drugs 2017, vol. 30, no. 6, pp. 1344–1350, 2007.
[27] R. Hartmann and H. Meisel, “Food-derived peptides with
2017, https ://diabe testa lk.net/pagin g/insul in/insul in-sales
biological activity: from research to food applications,”
-2016/.
Current Opinion in Biotechnology, vol. 18, no. 2, pp. 163–169,
[11] B. Deepthi, K. Sowjanya, B. Lidiya, R. Bhargavi, and P. Babu,
2007.
“A modern review of diabetes mellitus: an annihilatory
[28] J. Nehete, M. Narkhede, R. Bhambar, and S. Gawali, “Natural
metabolic disorder,” Journal of In Silico In Vitro Pharmacol,
proteins: sources, isolation, characterization and applica-
vol. 3, p. 14, 2017.
tions,” Pharmacognosy Reviews, vol. 7, no. 14, pp. 107–116,
[12] S. P. Patil, A. Goswami, K. Kalia, and A. S. Kate, “Plant-
2013.
derived bioactive peptides: a treatment to cure diabetes,”
[29] K. Lindsey, S. Casson, and P. Chilley, “Peptides: new sig-
International Journal of Peptide Research and Therapeutics,
nalling molecules in plants,” Trends in Plant Science, vol. 7,
vol. 26, no. 2, pp. 955–968, 2020. no. 2, pp. 78–83, 2002.
[13] V. Loganathan, Growth Potential in Peptide and Protein [30] J. M. Van Norman, N. W. Breakfield, and P. N. Benfey,
Therapeutics to Enhance Supplier Capacities [Online], 2016, “Intercellular communication during plant development,”
https://www.beroe inc.com/white paper/pepti desprote ins/. The Plant Cell Online, vol. 23, no. 3, pp. 855–864, 2011.
[14] A. Lund, F. K. Knop, and T. Vilsbøll, “Glucagon-like peptide- [31] E. Murphy, S. Smith, and I. De Smet, “Small signaling
1 receptor agonists for the treatment of type 2 diabetes: peptides in arabidopsis development: how cells communi-
differences and similarities,” European Journal of Internal cate over a short distance,” The Plant Cell Online, vol. 24,
Medicine, vol. 25, no. 5, pp. 407–414, 2014. no. 8, pp. 3198–3217, 2012.
[15] P. W. Duda, M. C. Schmied, S. L. Cook, J. I. Krieger, and [32] S. Ghorbani, “Signaling peptides in plants,” Cell Devision
D. A. Hafler, “Glatiramer acetate (Copaxone) induces de- Biology, vol. 3, no. 2, Article ID 1000141, 2014.
generate, Th2-polarized immune responses in patients with [33] H. L. Bleich, M. J. Moore, J. Roth, D. LeRoith, J. Shiloach, and
multiple sclerosis,” Journal of Clinical Investigation, vol. 105, J. L. Rosenzweig, “The evolutionary origins of hormones,
no. 7, pp. 967–976, 2000. neurotransmitters, and other extracellular chemical mes-
[16] V. N. Brito, A. C. Latronico, and B. B. Mendonca, “A single sengers: implications for mammalian biology,” New England
luteinizing hormone determination 2 hours after depot Journal of Medicine, vol. 306, no. 9, pp. 523–527, 1982.
leuprolide is useful for therapy monitoring of gonadotropin- [34] E. Collier, A. Watkinson, C. F. Cleland, and J. Roth, “Partial
dependent precocious puberty in girls,” The Journal of purification and characterization of an insulin-like material
Clinical Endocrinology & Metabolism, vol. 89, no. 9, from spinach and lemna gibba G3,” Journal of Biological
pp. 4338–4342, 2004. Chemistry, vol. 262, no. 13, pp. 6238–6247, 1987.10 Evidence-Based Complementary and Alternative Medicine
[35] M. Fukushima, S. Watanabe, and K. Kushima, “Extraction gastrointestinal digestion,” Journal of Functional Foods,
and purification of a substance with luteinizing hormone vol. 35, pp. 531–539, 2017.
releasing activity from the leaves of Avena sativa,” Tohoku [51] S. Jha, S. K. Gupta, P. Bhattacharyya, A. Ghosh, and
Journal of Experimental Medicine, vol. 119, no. 2, pp. 115– P. Mandal, “In vitro antioxidant and antidiabetic activity of
122, 1976. oligopeptides derived from different mulberry (Morus alba
[36] D. Leroith, W. Pickens, G. L. Wilson et al., “Somatostatin- L.) cultivars,” Pharmacognosy Research, vol. 10, no. 4, p. 361,
like material is present in flowering plants,” Endocrinology, 2018.
vol. 117, no. 5, pp. 2093–2097, 1985. [52] S. Marella, D. R. Maddirela, E. G. Kumar, T. K. Tilak,
[37] J. E. Morley, N. Meyer, A. E. Pekary et al., “A prolactin K. R. Badri, and A. Chippada, “Mcy protein, a potential
inhibitory factor with immunocharacteristics similar to antidiabetic agent: evaluation of carbohydrate metabolic
thyrotropin releasing factor (TRH) is present in rat pituitary enzymes and antioxidant status,” International Journal of
tumors (GH3 and W5), testicular tissue and a plant material, Biological Macromolecules, vol. 86, pp. 481–488, 2016.
alfalfa,” Biochemical and Biophysical Research Communica- [53] M. H. Alu’datt, K. Ereifej, A. Abu-Zaiton et al., “Anti-oxi-
tions, vol. 96, no. 1, pp. 47–53, 1980. dant, anti-diabetic, and anti-hypertensive effects of extracted
[38] T. E. Creighton, Proteins: Structures and Molecular Prop- phenolics and hydrolyzed peptides from barley protein
erties, Macmillan, New York, NY, USA, 1993. fractions,” International Journal of Food Properties, vol. 15,
[39] J. Gueguen and P. Cerletti, “Proteins of some legume seeds: no. 4, pp. 781–795, 2012.
soybean, pea, fababean and lupin,” in New and Developing [54] K. Alagesan, P. K. Raghupathi, and S. Sankarnarayanan,
Sources of Food Proteins, B. J. F. Hudson, Ed., Springer, “Amylase inhibitors: potential source of anti-diabetic drug
Boston, MA, USA, 1994. discovery from medicinal plants,” International Journal of
[40] H. Y. Lo, C. C. Li, T. Y. Ho, and C. Y. Hsiang, “Identification Pharmacy Life Science, vol. 3, pp. 1407–1412, 2012.
of the bioactive and consensus peptide motif from [55] S. Jayaraj, S. Suresh, and R. K. Kadeppagari, “Amylase in-
Momordica charantia insulin receptor-binding protein,” hibitors and their biomedical applications,” Starch-Stärke,
Food Chemistry, vol. 204, pp. 298–305, 2016. vol. 65, no. 7-8, pp. 535–542, 2013.
[41] A. J. Scheen, “Is there a role for α-glucosidase inhibitors in [56] Y. Y. Ngoh and C. Y. Gan, “Enzyme-assisted extraction and
the prevention of type 2 diabetes mellitus?” Drugs, vol. 63, identification of antioxidative and alpha-amylase inhibitory
peptides from Pinto beans (Phaseolus vulgaris cv. Pinto),”
no. 10, pp. 933–951, 2003.
[42] A. D. Mooradian and J. E. Thurman, “Drug therapy of Food Chemistry, vol. 190, pp. 331–337, 2016.
[57] H. L. Siow and C. Y. Gan, “Extraction, identification, and
postprandial hyperglycaemia,” Drugs, vol. 57, no. 1,
structure– activity relationship of antioxidative and α-am-
pp. 19–29, 1999.
ylase inhibitory peptides from cumin seeds (Cuminum
[43] A. Ceriello, M. Hanefeld, L. Leiter et al., “Postprandial
cyminum),” Journal of Functional Foods, vol. 22, pp. 1–12,
glucose regulation and diabetic complications,” Arch In-
2016.
ternational Medicine, vol. 164, no. 19, pp. 2090–2095, 2004.
[58] T. Kodama, T. Miyazaki, I. Kitamura et al., “Effects of single
[44] T. Salvatore and D. Giugliano, “Pharmacokinetic-pharma-
and long-term administration of wheat albumin on blood
codynamic relationships of acarbose,” Clinical Pharmaco-
glucose control: randomized controlled clinical trials,” Eu-
kinetics, vol. 30, no. 2, pp. 94–106, 1996.
ropean Journal of Clinical Nutrition, vol. 59, no. 3,
[45] Y. Ren, K. Liang, Y. Jin et al., “Identification and charac-
pp. 384–392, 2005.
terization of two novel α-glucosidase inhibitory oligopep-
[59] N. G. Gonzalez Garza, J. A. Chuc Koyoc, J. A. Torres Castillo
tides from hemp (Cannabis sativa L.) seed protein,” Journal et al., “Biofunctional properties of bioactive peptide fractions
of Functional Foods, vol. 26, pp. 439–450, 2016. from protein isolates of moringa seed (Moringa oleifera),”
[46] H. Zhang, J. Wang, Y. Liu, and B. Sun, “Peptides derived Journal of Food Science & Technology, vol. 54, no. 13,
from oats improve insulin sensitivity,” Journal of Biomedical pp. 4268–4276, 2017.
Science, vol. 4, pp. 1–7, 2015. [60] R. O. Arise, “In vitro antioxidant and α-amylase inhibitory
[47] J. Wang, K. Du, L. Fang, C. Liu, W. Min, and J. Liu, properties of watermelon seed protein hydrolysates,” Envi-
“Evaluation of the antidiabetic activity of hydrolyzed pep- ronmental and Experimental Biology, vol. 14, no. 4,
tides derived from Juglans mandshurica maxim fruits in pp. 163–172, 2016.
insulin-resistant HepG2 cells and type 2 diabetic mice,” [61] B. Sarmadi, F. Aminuddin, M. Hamid, N. Saari, A. Abdul-
Journal of Food Biochemistry, vol. 42, no. 3, Article ID Hamid, and A. Ismail, “Hypoglycemic effects of cocoa
e12518, 2018. (Theobroma cacao L.) autolysates,” Food Chemistry, vol. 134,
[48] Y. Yao, X. Cheng, and G. Ren, “α-Glucosidase inhibitory no. 2, pp. 905–911, 2012.
activity of protein-rich extracts from extruded adzuki bean in [62] M. Ayoub and D. Scheidegger, “Peptide drugs, overcoming
diabetic KK-Ay mice,” Food & Function, vol. 5, pp. 966–971, the challenges, a growing business,” Chimica Oggi, vol. 24,
2014. p. 46, 2006.
[49] M. E. Oseguera-Toledo, E. Gonzalez de Mejia, and [63] D. J. Drucker and M. A. Nauck, “The incretin system: glu-
S. L. Amaya-Llano, “Hard-to-cook bean (Phaseolus vulgaris cagon-like peptide-1 receptor agonists and dipeptidyl pep-
L.) proteins hydrolyzed by alcalase and bromelain produced tidase-4 inhibitors in type 2 diabetes,” The Lancet, vol. 368,
bioactive peptide fractions that inhibit targets of type-2 pp. 1696–1705, 2006.
diabetes and oxidative stress,” Food Research International, [64] A. Barnett, “DPP-4 inhibitors and their potential role in the
vol. 76, pp. 839–851, 2015. management of type 2 diabetes,” International Journal of
[50] R. Vilcacundo, C. Martı́nez-Villaluenga, and B. Hernández- Clinical Practice, vol. 60, no. 11, pp. 1454–1470, 2006.
Ledesma, “Release of dipeptidyl peptidase IV, α-amylase and [65] T. Hatanaka, M. Uraji, A. Fujita, and K. Kawakami, “Anti-
α-glucosidase inhibitory peptides from quinoa (Chenopo- oxidation activities of rice-derived peptides and their in-
dium quinoa Willd.) during in vitro simulated hibitory effects on dipeptidylpeptidase-IV,” InternationalEvidence-Based Complementary and Alternative Medicine 11
Journal of Peptide Research Therpy, vol. 21, no. 4, pp. 479– protein extract from fruit pulp of Momordica charantia with
485, 2015. insulin secretagogue and insulinomimetic activities,” Bio-
[66] T. Hatanaka, Y. Inoue, J. Arima et al., “Production of logical and Pharmaceutical Bulletin, vol. 29, no. 6,
dipeptidyl peptidase IV inhibitory peptides from defatted pp. 1126–1131, 2006.
rice bran,” Food Chemistry, vol. 134, no. 2, pp. 797–802, 2012. [81] P. Khanna, S. C. Jain, A. Panagariya, and V. P. Dixit,
[67] A. J. Velarde-Salcedo, A. Barrera-Pacheco, S. Lara-Gonzalez “Hypoglycemic activity of polypeptide-p from a plant
et al., “In vitro inhibition of dipeptidyl peptidase IV by source,” Journal of Natural Products, vol. 44, no. 6,
peptides derived from the hydrolysis of amaranth (Amar- pp. 648–655, 1981.
anthus hypochondriacus L.) proteins,” Food Chemistry, [82] M. D. Rajasekhar, K. R. Badri, K. Vinay Kumar et al.,
vol. 136, no. 2, pp. 758–764, 2013. “Isolation and characterization of a novel antihyperglycemic
[68] C. Lammi, C. Zanoni, A. Arnoldi, and G. Vistoli, “Peptides protein from the fruits of Momordica cymbalaria,” Journal of
derived from soy and lupin protein as dipeptidyl-peptidase Ethnopharmacology, vol. 128, no. 1, pp. 58–62, 2010.
IV inhibitors: in vitro biochemical screening and in silico [83] C. Roblet, A. Doyen, J. Amiot, G. Pilon, A. Marette, and
molecular modeling study,” Journal of Agriculture Food L. Bazinet, “Enhancement of glucose uptake in muscular cell
Chemistry, vol. 64, no. 51, pp. 9601–9606, 2016. by soybean charged peptides isolated by electrodialysis with
[69] L. Mojica, E. Gonzalez de Mejia, M. Á. Granados-Silvestre, ultrafiltration membranes (EDUF): activation of the AMPK
and M. Menjivar, “Evaluation of the hypoglycemic potential pathway,” Food Chemistry, vol. 147, pp. 124–130, 2014.
of a black bean hydrolyzed protein isolate and its pure [84] C. M. Teugwa, T. Boudjeko, B. T. Tchinda, P. C. Mejiato, and
peptides using in silico, in vitro and in vivo approaches,” D. Zofou, “Anti-hyperglycaemic globulins from selected
Journal of Functional Foods, vol. 31, pp. 274–286, 2017a. cucurbitaceae seeds used as antidiabetic medicinal plants in
[70] L. Mojica, D. A. Luna-Vital, and E. Gonzalez de Mejia, Africa,” BMC Complementary and Alternative Medicine,
“Characterization of peptides from common bean protein vol. 13, no. 1, p. 63, 2013.
isolates and their potential to inhibit markers of type-2 di- [85] C. R. Azevedo, F. M. Maciel, L. B. Silva et al., “Isolation and
abetes, hypertension and oxidative stress,” Journal of the intracellular localization of insulin-like proteins from leaves
Science of Food and Agriculture, vol. 97, no. 8, pp. 2401–2410, of Bauhinia variegata,” Brazilian Journal of Medicine Biology
2017b. Research, vol. 39, no. 11, pp. 1435–1444, 2006.
[71] P. A. Estrada-Salas, G. M. Montero-Moran, P. P. Martinez- [86] T. Hira, T. Mochida, K. Miyashita, and H. Hara, “GLP-1
Cuevas, C. Gonzalez, and A. P. Barba de la Rosa, “Char- secretion is enhanced directly in the ileum but indirectly in
acterization of antidiabetic and antihypertensive properties the duodenum by a newly identified potent stimulator, zein
of canary seed (Phalaris canariensis L.) peptides,” Journal of hydrolysate, in rats,” American Journal of Physiology -
Agriculture Food Chemistry, vol. 62, no. 2, pp. 427–433, 2014. Gastrointestinal and Liver Physiology, vol. 297, no. 4,
[72] A. B. Nongonierma, S. Le Maux, C. Dubrulle, C. Barre, and pp. 663–671, 2009.
R. J. Fitzgerald, “Quinoa (Chenopodium quinoa Willd.) [87] J. Lu, Y. Zeng, W. Hou et al., “The soybean peptide aglycin
protein hydrolysates with in vitro dipeptidyl peptidase IV regulates glucose homeostasis in type 2 diabetic mice via IR/
(DPP-IV) inhibitory and antioxidant properties,” Journal of IRS1 pathway,” The Journal of Nutritional Biochemistry,
Cereal Science, vol. 65, pp. 112–118, 2015. vol. 23, no. 11, pp. 1449–1457, 2012.
[73] G. Musso, R. Gambino, M. Cassader, and G. Pagano, “A [88] Y. Yamada, A. Muraki, M. Oie et al., “Soymorphin-5, a soy-
novel approach to control hyperglycemia in type 2 diabetes: derived μ-opioid peptide, decreases glucose and triglyceride
sodium glucose cotransport (SGLT) inhibitors: systematic levels through activating adiponectin and PPARα systems in
review and meta-analysis of randomized trials,” Annals of diabetic KKAy mice,” American Journal of Physiology. En-
Medicine, vol. 44, no. 4, pp. 375–393, 2012. docrinology and Metabolism, vol. 302, no. 4, pp. E433–E440,
[74] G. K. Brown, “Glucose transporters: structure, function and 2012.
consequences of deficiency,” Journal of Inheritance Meta- [89] K. Boonloh, V. Kukongviriyapan, B. Kongyingyoes,
bolism Diseases, vol. 23, no. 3, pp. 237–246, 2000. U. Kukongviriyapan, S. Thawornchinsombut, and
[75] R. P. Nankar and M. Doble, “Non-peptidyl insulin mimetics P. Pannangpetch, “Rice bran protein hydrolysates improve
as a potential antidiabetic agent,” Drug Discovery Today, insulin resistance and decrease pro-inflammatory cytokine
vol. 18, no. 15-16, pp. 748–755, 2013. gene expression in rats fed a high carbohydrate-high fat
[76] S. R. Stapleton, “Selenium: an insulin mimetic,” Cellular and diet,” Nutrients, vol. 7, no. 8, pp. 6313–6329, 2015.
Molecular Life Sciences, vol. 57, no. 13, pp. 1874–1879, 2000. [90] S. Poovitha, M. Siva Sai, and M. Parani, “Protein extract from
[77] F. Uruakp, “Influence of cowpea (Vigna unguiculata) pep- the fruit pulp of Momordica dioica shows anti-diabetic, anti-
tides on insulin resistance,” Journal of Nutritional Health & lipidemic and antioxidant activity in diabetic rats,” Journal of
Food Science, vol. 3, no. 2, pp. 1–3, 2015. Functional Foods, vol. 33, pp. 181–187, 2017.
[78] A. Doyen, C. C. Udenigwe, P. L. Mitchell, A. Marette, [91] J. Xavier-Filho, A. E. A. Oliveira, L. B. D. Silva et al., “Plant
R. E. Aluko, and L. Bazinet, “Anti-diabetic and antihyper- insulin or glucokinin: a conflicting issue,” Brazilian Journal
tensive activities of two flaxseed protein hydrolysate fractions of Plant Physiology, vol. 15, no. 2, pp. 67–78, 2003.
revealed following their simultaneous separation by elec- [92] M. Morishita and N. A. Peppas, “Is the oral route possible for
trodialysis with ultrafiltration membranes,” Food Chemistry, peptide and protein drug delivery?” Drug Discovery Today,
vol. 145, pp. 66–76, 2014. vol. 11, no. 19-20, pp. 905–910, 2006.
[79] X. Yuan, X. Gu, and J. Tang, “Purification and character- [93] H. Baynes, “Classification, pathophysiology, diagnosis and
isation of a hypoglycemic peptide from Momordica Char- management of diabetes mellitus,” Journal of Diabetes &
antia L. Var. abbreviata Ser,” Food Chemistry, vol. 111, no. 2, Metabolism, vol. 6, pp. 1–9, 2015.
pp. 415–420, 2008. [94] D. J. Craik, D. P. Fairlie, S. Liras, and D. Price, “The future of
[80] S. Yibchok-Anun, S. Adisakwattana, C. Y. Yao, peptidebased drugs,” Chemical Biology & Drug Design,
P. Sangvanich, S. Roengsumran, and W. H. Hsu, “Slow acting vol. 81, no. 1, pp. 136–147, 2013.You can also read
